Stock Track | Vir Biotechnology Soars 8% Pre-market on Successful Initiation of Chronic Hepatitis Delta Trials

Stock Track

Aug 06, 2025

Vir Biotechnology, Inc. (VIR) saw its stock surge 8.02% in pre-market trading on Wednesday, following the announcement of significant progress in its chronic hepatitis delta (CHD) treatment program. The biotechnology company has successfully initiated all trials in its ECLIPSE registrational program, marking a major milestone in its efforts to address this serious liver disease.

The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that forms a crucial part of the registrational program. This trial aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE program is designed to provide supportive data for establishing access and reimbursement in key markets, potentially paving the way for a new treatment option for CHD patients.

Investors appear to be responding positively to this development, recognizing the potential impact of Vir Biotechnology's innovative approach to treating chronic hepatitis delta. The combination therapy of tobevibart and elebsiran has already received several designations from regulatory agencies, highlighting its potential in addressing unmet medical needs in CHD. While the results of these trials are yet to be presented, the successful initiation of the entire ECLIPSE program signals a significant step forward in Vir Biotechnology's clinical development efforts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179853686"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179853686\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179853686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179853686","market":"us","top_or_hot":-1,"title":"Stock Track | Vir Biotechnology Soars 8% Pre-market on Successful Initiation of Chronic Hepatitis Delta Trials","media":"Stock Track","content":"<p>Vir Biotechnology, Inc. (VIR) saw its stock surge 8.02% in pre-market trading on Wednesday, following the announcement of significant progress in its chronic hepatitis delta (CHD) treatment program. The biotechnology company has successfully initiated all trials in its ECLIPSE registrational program, marking a major milestone in its efforts to address this serious liver disease.</p>\n\n<p>The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that forms a crucial part of the registrational program. This trial aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE program is designed to provide supportive data for establishing access and reimbursement in key markets, potentially paving the way for a new treatment option for CHD patients.</p>\n\n<p>Investors appear to be responding positively to this development, recognizing the potential impact of Vir Biotechnology's innovative approach to treating chronic hepatitis delta. The combination therapy of tobevibart and elebsiran has already received several designations from regulatory agencies, highlighting its potential in addressing unmet medical needs in CHD. While the results of these trials are yet to be presented, the successful initiation of the entire ECLIPSE program signals a significant step forward in Vir Biotechnology's clinical development efforts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotechnology Soars 8% Pre-market on Successful Initiation of Chronic Hepatitis Delta Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotechnology Soars 8% Pre-market on Successful Initiation of Chronic Hepatitis Delta Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-06 20:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology, Inc. (VIR) saw its stock surge 8.02% in pre-market trading on Wednesday, following the announcement of significant progress in its chronic hepatitis delta (CHD) treatment program. The biotechnology company has successfully initiated all trials in its ECLIPSE registrational program, marking a major milestone in its efforts to address this serious liver disease.</p>\n\n<p>The company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that forms a crucial part of the registrational program. This trial aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE program is designed to provide supportive data for establishing access and reimbursement in key markets, potentially paving the way for a new treatment option for CHD patients.</p>\n\n<p>Investors appear to be responding positively to this development, recognizing the potential impact of Vir Biotechnology's innovative approach to treating chronic hepatitis delta. The combination therapy of tobevibart and elebsiran has already received several designations from regulatory agencies, highlighting its potential in addressing unmet medical needs in CHD. While the results of these trials are yet to be presented, the successful initiation of the entire ECLIPSE program signals a significant step forward in Vir Biotechnology's clinical development efforts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1179853686","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179853686","pubTimestamp":1754483918,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vir Biotechnology, Inc. (VIR) saw its stock surge 8.02% in pre-market trading on Wednesday, following the announcement of significant progress in its chronic hepatitis delta (CHD) treatment program....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"个股追踪|Vir Biotechnology盘前大涨8%，成功启动慢性肝炎德尔塔试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology, Inc. (VIR) saw its stock surge 8.02% in pre-market trading on Wednesday, following the announcement of significant progress in its chronic hepatitis delta (CHD) treatment program. The biotechnology company has successfully initiated all trials in its ECLIPSE registrational program, marking a major milestone in its efforts to address this serious liver disease.\nThe company reported the enrollment of the first participant in ECLIPSE 3, a Phase 2b trial that forms a crucial part of the registrational program. This trial aims to compare the combination treatment of tobevibart and elebsiran with bulevirtide in CHD patients. The ECLIPSE program is designed to provide supportive data for establishing access and reimbursement in key markets, potentially paving the way for a new treatment option for CHD patients.\nInvestors appear to be responding positively to this development, recognizing the potential impact of Vir Biotechnology's innovative approach to treating chronic hepatitis delta. The combination therapy of tobevibart and elebsiran has already received several designations from regulatory agencies, highlighting its potential in addressing unmet medical needs in CHD. While the results of these trials are yet to be presented, the successful initiation of the entire ECLIPSE program signals a significant step forward in Vir Biotechnology's clinical development efforts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}